Latest news with #AurobindoPharma
Economic Times
2 days ago
- Business
- Economic Times
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330
ICICI Securities has downgraded Aurobindo Pharma to Add (from Buy earlier) with a revised target price of Rs 1,330 (earlier Rs 1,445). The current market price of Aurobindo Pharma Ltd. is Rs 1147.95. Aurobindo Pharma, incorporated in 1986, is a Large Cap company with a market cap of Rs 66664.41 crore, operating in the Pharmaceuticals sector. ADVERTISEMENT Aurobindo Pharma's key products/revenue segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2024. Financials For the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 8516.93 crore, up 4.68 % from last quarter Total Income of Rs 8135.81 crore and up 10.38 % from last year same quarter Total Income of Rs 7715.77 crore. The company has reported net profit after tax of Rs 935.02 crore in the latest quarter. The company's top management includes Mr.M Ramasubramanian Kumar, Mukherjee, Mahajan, P Vanvari, Mr.P Sarath Chandra Reddy, Makkapati, Mr.P V Ramprasad Reddy, Mr.M Madan Mohan Reddy, Mr.K Nithyananda Reddy, Pant Joshi. Company has Deloitte Haskins & Sells as its auditors. As on 31-03-2025, the company has a total of 58 Crore shares outstanding. Investment Rationale ADVERTISEMENT Aurobindo Pharma?s US sales growth (up 8.8% YoY to $470 million) in Q4FY25 was driven by gRevlimid; however, sales run-rate is likely to come down in FY26 as pricing competition intensifies, manufacturing at Pen-G plant has been temporarily halted due to fire in the coal yard near conveyor belt. However, production may resume soon post approval from Andhra Pradesh Pollution Control Board which the management expects in next couple of months. Europe business continues to grow at a faster pace and going ahead new launches may boost growth. Management expects traction in Europe to improve ahead led by new product launches and will launch biosimilars in Europe and UK in Q2FY26. Aurobindo has signed a definitive agreement with Merck Sharpe and Dohme (MSD Singapore) for contract manufacturing of innovative biologics, civil work on this plant is on and in FY27 it expects to commission this plant; revenue generation to start in FY28. ICICI Securities lowered its FY26/27E EBITDA by ~12%/8%, respectively, to factor in lower sales from Eugia. The stock currently trades at 17.1x FY26E and 14.3x FY27E earnings, and EV/EBITDA multiples of 9.1x FY26E and 7.6x FY27E. They have lowered rating on the stock to ADD (from Buy) with lower target price of Rs 1,330 (Rs 1,445 earlier), based on 16x FY27E EPS (18x FY26E EPS earlier). Key downside risks include regulatory hurdles, currency volatility and delay in US launches. Promoter/FII Holdings Promoters held 51.82 per cent stake in the company as of 31-Mar-2025, while FIIs owned 15.33 per cent, DIIs 26.23 per cent. (You can now subscribe to our ETMarkets WhatsApp channel) Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.
Time of India
2 days ago
- Business
- Time of India
I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330
ICICI Securities has downgraded Aurobindo Pharma to 'Add' with a revised target price of Rs 1,330, citing potential decline in gRevlimid sales due to pricing competition and a temporary halt in Pen-G plant production. While Europe business shows promise with new launches and biosimilars, lowered FY26/27E EBITDA reflects anticipated lower sales from Eugia. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads (Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.)
Time of India
2 days ago
- Business
- Time of India
Top stocks to buy today: Stock recommendations for May 30, 2025
Stock market recommendations: According to Bajaj Broking Research, Aurobindo Pharma, and Gokaldas Exports are the top stock picks for today. Here's its view on Nifty, Bank Nifty and the top stock picks for May 30, 2025: Index View: NIFTY Benchmark indices extended consolidation for the second week in a row amid stock specific action. Tired of too many ads? go ad free now Nifty is seen consolidating in the range of 24,400-25,200. Despite facing multiple global macroeconomic and geopolitical headwinds — including heightened geopolitical tensions, persistent global trade tariff uncertainties, and elevated U.S. bond yields — the Indian equity market continues to exhibit a resilient upward bias. The benchmark index has sustained its positive trajectory and is now placed around the 24,800 level. From a short-term technical perspective, the market sentiment remains constructive. The index is expected to find strong demand in the support zone of 24,400–24,500. As long as this key support range is held, we anticipate the Nifty 50 to continue its bullish momentum towards the resistance at 25,200-25,300 levels in the short term. Short-term support for Nifty is placed at 24,400–24,500 levels being confluence of 20 days EMA, previous breakout area and the last 2 weeks lows. While on the higher side 25,200-25,300 remains a key hurdle area being the previous major high and 80% retracement of the entire decline (26.277-21,744). Factors that support the positive momentum in the market 1) Rate cut expectations in the monetary policy outcome (2) Above normal Monsoon Forecast by the Indian Meteorological Department (IMD) (3) Brent crude prices have remained in a downward trajectory, offering a major tailwind to the Indian economy, which is a net importer of crude. Tired of too many ads? go ad free now NIFTY BANK Bank Nifty continues to consolidate in the broad range of 56,000-53,500 in the last 5 weeks. A key technical observation on the daily chart is that the index has already taken 26 sessions; it has retraced just 38.2% of the prior 9-session rally (49,157–56,098), indicating a shallow pullback that suggests underlying strength and potential higher bottom formation. We expect the index to extend the last 5 weeks' consolidation in the range of 53,500-56,000. Only a move above 56,000 levels will signal acceleration of the up move towards 56,700 levels in the coming sessions. Within consolidation we believe dips should be used as a buying opportunity. Key support placed at 54,000-53,500 as it is the confluence of the lower band of the last 5 weeks range, key retracement and 50 days EMA. Stock Recommendations: Aurobindo Pharma Buy in the range of Rs 1155-1175 Target SL Return Time Period Rs 1278 1109 10% 3 Months The stock is rebounding taking support at the rising trendline support joining lows of the last 3 months signaling buying demand at lower levels. The daily stochastic is rebounding from the oversold territory and has generated a buy signal moving above its three periods average thus validates positive bias. We expect the stock to head towards 1278 levels in the coming months being the 80% retracement of the previous decline (1356-1010) and the high of April 2025. Gokaldas Exports Buy in the range of Rs 960-980 Target SL Return Time Period Rs 1090 905 12% 3 Months The stock is witnessing buying demand from the previous major breakout area and the confluence of 20- & 50-days EMA signaling strength and offers fresh entry opportunity. It is currently trading above the short- and long-term moving averages signaling strength and overall positive bias. The daily stochastic is rebounding from the oversold territory and has generated a buy signal moving above its three periods average thus validates positive bias. We expect the stock to head towards 1090 levels in the coming months being the 123.6% external retracement of the previous decline (1060-925). Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
Business Standard
3 days ago
- Business
- Business Standard
Aurobindo Pharma arm incorporates WOS in Netherlands
Aurobindo Pharma said that its wholly owned subsidiary, Curateq Biologics has incorporated a new wholly owned subsidiary (WOS) in the Netherlands by the name of CuraTeQ Biologics B.V. The purpose of the incorporation of this wholly owned subsidiary is to expand the Biopharma Products business in Europe. The company has subscribed to an initial share capital of Euro 10,000, divided into 10,000 shares with a nominal value of Euro 1.00 each. Aurobindo Pharma is an integrated global pharmaceutical company headquartered in Hyderabad, India. The company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The companys consolidated net profit fell 0.6% to Rs 903.47 crore despite a 11.9% jump in net sales to Rs 8,381.12 crore in Q4 FY25 over Q4 FY24. The scrip declined 3.61% to end at Rs 1,147.95 on the BSE.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
These 5 pharma stocks can fall up to 12% as technical charts flag caution
Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for. Premium Rex Cano Mumbai Listen to This Article Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma are the 5 pharma stocks that have flagged a caution signal on the technical charts. Technically, these 5 stocks have seen a negative crossover of the key momentum oscillators like - the Relative Strength Index (RSI), Stochastic Slow or the Moving Average Convergence-Divergence (MACD) on the daily scale. Negative crossover of key momentum oscillators, coupled with violation of key support levels tends to weigh on the stock sentiment. Here's a detailed technical analysis of each of these 5 stocks - Abbott India, Aurobindo Pharma, Cipla, Dr Lal
